Drug
Nicotine Lozenges
Nicotine Lozenges is a pharmaceutical drug with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 4 completed trials
Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
50%(2 trials)
Phase Distribution
Ph not_applicable
1
25%
Ph phase_1
1
25%
Ph phase_3
1
25%
Ph phase_2
1
25%
Phase Distribution
1
Early Stage
1
Mid Stage
1
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
1(25.0%)
N/ANon-phased studies
1(25.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
4 of 4 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(4)
Detailed Status
Completed4
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 11 (25.0%)
Phase 21 (25.0%)
Phase 31 (25.0%)
N/A1 (25.0%)
Trials by Status
completed4100%
Recent Activity
0 active trials
Showing 4 of 4
completednot_applicable
Comparing Two Behavioral Approaches to Quitting Smoking in Mental Health Settings
NCT05030272
completedphase_1
First Time in Human Study With GSK1018921
NCT00527020
completedphase_2
Nicotine Lozenge or Tobacco-Free Snuff for Smokeless Tobacco Reduction
NCT01018394
completedphase_3
Nicotine Lozenges for Treatment of Smokeless Tobacco Addiction
NCT00392379
Clinical Trials (4)
Showing 4 of 4 trials
NCT05030272Not Applicable
Comparing Two Behavioral Approaches to Quitting Smoking in Mental Health Settings
NCT00527020Phase 1
First Time in Human Study With GSK1018921
NCT01018394Phase 2
Nicotine Lozenge or Tobacco-Free Snuff for Smokeless Tobacco Reduction
NCT00392379Phase 3
Nicotine Lozenges for Treatment of Smokeless Tobacco Addiction
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4